Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 11,433 matching trials from the live ClinicalTrials.gov search.
Conditions
Gastrointestinal Stromal Tumors
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo, Best supportive care
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • Evanston, Illinois • Skokie, Illinois + 6 more
Conditions
Recurrent Childhood Brain Tumor
Interventions
Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib
Device · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Urothelial Carcinoma
Interventions
disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
89
States / cities
Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more
Conditions
Thyroid Eye Disease
Interventions
Veligrotug
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 13 more
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol

NCT01079130
Conditions
Asthma
Interventions
Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
71
States / cities
Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more
Conditions
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methylphenidate hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
238
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 155 more
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
E/C/F/TAF, E/C/F/TAF (Low Dose)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Conditions
B-cell Small Lymphocytic Lymphoma Recurrent
Interventions
TRU-016, Bendamustine, Rituximab
Drug
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Birmingham, Alabama • Augusta, Georgia • Omaha, Nebraska + 3 more
Conditions
Cerebral Amyloid Angiopathy
Interventions
Placebo, ALN-APP
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
34
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 27 more
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Tucson, Arizona • Orland Park, Illinois • Ann Arbor, Michigan + 8 more
Completed Phase 4 Interventional Results available

Late-Onset Treatment Study Extension Protocol

NCT00455195
Conditions
Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II, Acid Maltase Deficiency (AMD)
Interventions
alglucosidase alfa
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
8 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Anchorage, Alaska • Phoenix, Arizona • Beverly Hills, California + 23 more
Conditions
Colitis, Ulcerative
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Headache
Interventions
Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone, Placebo Pteryogpalatine Fossa Injection
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Gainesville, Florida • Miami, Florida • Stuart, Florida + 10 more
Conditions
Newly Diagnosed AML With FLT3 Activating Mutations
Interventions
crenolanib, cytarabine, daunorubicin, idarubicin
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Duarte, California • Iowa City, Iowa • Boston, Massachusetts + 5 more
Completed No phase listed Observational Results available

Fibromyalgia Health Outcome Study on Cost of Treatments

NCT00725101
Conditions
Fibromyalgia
Interventions
Treatment for Fibromyalgia
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
49
States / cities
Hot Springs, Arkansas • Santa Barbara, California • Danbury, Connecticut + 46 more
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
66
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 42 more
Conditions
Colorectal Carcinoma, Lynch Syndrome
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 5 more
Completed Not applicable Interventional Accepts healthy volunteers

Considering Healthier Drinking Options in Collaborative Care

NCT01400581
Conditions
Alcohol Use Disorder
Interventions
Collaborative Care Intervention
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 64 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
40
States / cities
Downy, California • Fountain Valley, California • Fullerton, California + 37 more
Conditions
Breast Neoplasms
Interventions
Lapatinib, Letrozole, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
84
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 78 more
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
ziv-aflibercept, topotecan hydrochloride
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
257
States / cities
Anniston, Alabama • Mobile, Alabama • Tucson, Arizona + 174 more
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Limited Versus Extended Trophic Feeding (LET-FEED) Trial

NCT06893939
Conditions
Sepsis, Length of Stay, Mortality, Neurodevelopmental Delay
Interventions
Limited Trophic Feeds (1 day of trophic feeds), Extended Trophic Feeds (3 days of trophics)
Other
Lead sponsor
University of Washington
Other
Eligibility
0 Years to 2 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
6
States / cities
Birmingham, Alabama • Tampa, Florida • Oklahoma City, Oklahoma + 3 more
Active, not recruiting Not applicable Interventional

TECTONIC CAD IVL IDE Study

NCT06885177
Conditions
Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Interventions
Experimental
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 33 more
Conditions
Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease
Interventions
Neihulizumab (ALTB-168)
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 10 more